VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 28, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted two U.S. Patents (No's 7,354,899 and 7,368,425).
